
News|Articles|November 1, 2006
Pipeline Preview (November 2006)
Lisdexamfetamine (NRP104, Shire/New River Pharmaceuticals) for the treatment of pediatric attention-deficit/hyperactivity disorder (ADHD)
Advertisement
Approvable designations
Fast-track designations
Orphan drug designations
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Nearly all Ryan White HIV/AIDS Program patients virally suppressed in 2024
2
Risk-based breast cancer screening reliable, preferred by women over annual screening, study shows
3
AI is emerging as key tool for Americans navigating the healthcare system, OpenAI report finds
4
Shekhar Khera of RxBenefits on the transformative impact of AI in healthcare
5






















































